Hepatitis C, Current Information On Hepatitis C &treatments for the medical professional and patient. | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search

Hepatitis C Virus Dynamics In Vivo: Effect of Ribavirin and Interferon Alfa on Viral Turnover

table  1.   Demographic, Biochemical, Serological, and Histological Profile of Patients With Chronic Hepatitis C Treated With 3 × 3 MU rIFN-, 3 × 6 MU rIFN-,, or 3 × 6 MU rIFN-, Per Week Plus Ribavirin (14 mg/kg of body weight per day)

Characteristics 3 × 3 MU rIFN-= SRC=”b_alpha.gif”> (N = 26) 3 × 6 MU rIFN-= SRC=”b_alpha.gif”> (N = 19) 3 × 6 MU rIFN-= SRC=”b_alpha.gif”> + ribavirin (N = 18)

Age (yr) 44 ± 13 43 ± 12 40 ± 11
Sex (M/F) 16/10 12/7  11/7 
Genotype
  HCV-1 17 12 11
  HCV-2 6 2 4
  HCV-3 3 5 3
Pretreatment HCV RNA+ 5.0 × 106 3.8 × 106 6.5 × 106
(0.15-100 × 106) (0.56-13 × 106) (0.24-38 × 106)
Serology
  Anti-HCV 26 19 18
  HBsAg 0 0 0
  Anti-HBc 7 9 6
  Anti-HIV 0 0 0
Laboratory data
  ALT (U/L) 79.3 ± 45.4 76.4 ± 47.2 53.1 ± 32.8
  AST (U/L) 41.3 ± 30.8 40.3 ± 20.3 31.6 ± 20.7
  Bilirubin (µmol/L) 11.3 ± 3.6  9.4 ± 7.8 10.5 ± 3.7 
  Albumin (g/L) 44 ± 9  49 ± 3  50 ± 3 
  -Globulin (g/L) 16 ± 5  15 ± 4  16 ± 5 
Liver histology
  Minimal activity 4 3 7
  Moderate activity 14 6 5
  Severe activity 5 9 2
  Active cirrhosis 3 1 4
Initial decline of HCV RNA below detection limit(genotype HCV-1, -2, -3) 10/26 (4, 4, 2) 10/19 (4, 2, 4) 10/18 (4, 4, 2)

 

 

Return To Article

Copyright © 1998 by the American Association for the Study of Liver Diseases.